- Previous Close
14,484.45 - Open
14,452.25 - Bid --
- Ask --
- Day's Range
14,049.00 - 14,531.10 - 52 Week Range
5,540.10 - 18,100.00 - Volume
14,736 - Avg. Volume
56,352 - Market Cap (intraday)
182.792B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
65.57 - EPS (TTM)
217.27 - Earnings Date Feb 10, 2025
- Forward Dividend & Yield 14.00 (0.10%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
18,075.00
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.neulandlabs.com1,643
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NEULANDLAB.NS
View MorePerformance Overview: NEULANDLAB.NS
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEULANDLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEULANDLAB.NS
View MoreValuation Measures
Market Cap
185.68B
Enterprise Value
184.80B
Trailing P/E
66.45
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.51
Price/Book (mrq)
13.32
Enterprise Value/Revenue
12.44
Enterprise Value/EBITDA
41.24
Financial Highlights
Profitability and Income Statement
Profit Margin
18.30%
Return on Assets (ttm)
12.13%
Return on Equity (ttm)
22.13%
Revenue (ttm)
15.28B
Net Income Avi to Common (ttm)
2.8B
Diluted EPS (ttm)
217.27
Balance Sheet and Cash Flow
Total Cash (mrq)
1.9B
Total Debt/Equity (mrq)
7.85%
Levered Free Cash Flow (ttm)
-28.64M